Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 9/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | PRKD2 | Q9BZL6 | 6/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313505 | 1.00 | PRKCZ (0.54) | PRKCZROCK1IKBKBAXLJAK2 | |
| SCHEMBL3313511 | 1.00 | PRKCZ (0.54) | PRKCZROCK1IKBKBAXLJAK2 | |
| Hydrochloric Acid SCHEMBL3311221 | 0.99 | PRKCZ (0.53) | PRKCZROCK1IKBKBAXLJAK2 | |
| Hydrochloric Acid SCHEMBL3311231 | 0.99 | PRKCZ (0.53) | PRKCZROCK1IKBKBAXLJAK2 | |
| SCHEMBL3313259 | 0.92 | PRKCZ (0.57) | PRKCZROCK1ITKPRKD2PRMT3 | |
| SCHEMBL3313263 | 0.92 | PRKCZ (0.57) | PRKCZROCK1ITKPRKD2PRMT3 | |
| SCHEMBL3318660 | 0.92 | IKBKB (0.51) | PRKCZROCK1IKBKBJAK2ROCK2 | |
| Hydrochloric Acid SCHEMBL3317013 | 0.91 | PRKCZ (0.56) | PRKCZROCK1ITKPRKD2PRMT3 | |
| Hydrochloric Acid SCHEMBL3317008 | 0.91 | PRKCZ (0.56) | PRKCZROCK1ITKPRKD2PRMT3 | |
| Hydrochloric Acid SCHEMBL29862903 | 0.90 | IKBKB (0.50) | PRKCZROCK1IKBKBJAK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2114920-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008077552-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077552-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | PRKCZ 94/4885ROCK1 5/4885IKBKB 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.